AI assistant
Cabaletta Bio, Inc. — Director's Dealing 2022
Jan 13, 2022
33628_dirs_2022-01-13_393173e4-f8a4-482c-923f-39a4ceee69cd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Cabaletta Bio, Inc. (CABA)
CIK: 0001759138
Period of Report: 2022-01-05
Reporting Person: Das Arun (Chief Business Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.01 | 2028-11-15 | Common Stock (29168) | Direct | |
| Stock Option (Right to Buy) | $11.00 | 2029-10-23 | Common Stock (18416) | Direct | |
| Stock Option (Right to Buy) | $11.47 | 2031-02-28 | Common Stock (35000) | Direct |
Footnotes
F1: 21,529 shares underlying this option have vested and the remainder shall vest in substantially equal monthly installments from January 16, 2022 to November 16, 2022, subject to the reporting person's continued service on each such vesting date.
F2: 25% of the shares underlying this option vested and became exercisable on October 24, 2020, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
F3: 25% of the shares underlying this option shall vest and become exercisable on March 1, 2022, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.